{"id":"NCT01795859","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"First Time Use of SD-809 in Huntington Disease","officialTitle":"A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-05","primaryCompletion":"2014-12-05","completion":"2014-12-05","firstPosted":"2013-02-21","resultsPosted":"2017-08-11","lastUpdate":"2017-09-20"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chorea"],"interventions":[{"type":"DRUG","name":"SD-809","otherNames":["deutetrabenazine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SD-809 ER Tablets","type":"EXPERIMENTAL"},{"label":"SD-809 Tablets","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.","primaryOutcome":{"measure":"Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12","timeFrame":"Screening, Day 0, Weeks 9, 12","effectByArm":[{"arm":"SD-809 Tablets","deltaMin":-4.42,"sd":2.953},{"arm":"SD-809 Placebo","deltaMin":-1.93,"sd":2.666}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":43,"countries":["United States","Australia","Canada"]},"refs":{"pmids":["39825184","38557959","29480210","28265459","27380342"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":45},"commonTop":["Irritability","Dry mouth","Somnolence","Fall","Dizziness"]}}